NCT05819866 - A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 12, 2023

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions

Cerebral Adrenoleukodystrophy (cALD)

Interventions

DRUG

Leriglitazone

Leriglitazone at a strength of 15 mg/ml. Once-daily dosing at an initial volume of 10 ml

DRUG

Placebo

Placebo will match the study drug visually and by taste

Trial Locations (13)

21205

RECRUITING

Kennedy Krieger Institute, Baltimore

28041

RECRUITING

Hospital 12 de Octubre, Madrid

32608

WITHDRAWN

Neuro Medicine Hospital / UF Health, Gainesville

55455

RECRUITING

University of Minnesota, Minneota

75013

RECRUITING

ICM La Pitie Salpetriere, Paris

84112

WITHDRAWN

Health University of Utah, Salt Lake City

110060

RECRUITING

Sir Ganga Ram Hospital, New Delhi

94304-5978

RECRUITING

Stanford University Medical Center, Palo Alto

02114

RECRUITING

Massachusetts General Hospital, Boston

Unknown

RECRUITING

Hospital Austral, Buenos Aires

RECRUITING

Federal University of Sao Paulo, São Paulo

04103

RECRUITING

Klinik und Poliklinik für Neurologie-Leipzig, Leipzig

WC1N 3AX

RECRUITING

National Hospital for Neurology and Neurosurgery, London